Mr. Hewett is a results-oriented leader with a legacy of growing and transforming healthcare and life science companies around the world. His deep domain expertise in developing growth strategies, building high performing teams, and mentoring executives allows him to navigate organizations through change effectively. Mr. Hewett joins SomaLogic, Inc. with 25+ years of commercial experience, almost entirely in the area of diagnostics. Most recently, he served as Chairman and CEO of BioBehavioral Diagnostics (BioBDx), a company offering the first FDA-cleared objective test for ADHD using proprietary technology. BioBDx was acquired by NCS Pearson in August 2013 as a key component to execute their strategy in ADHD. Prior to his work with BioBDx, Mr. Hewett was President and CEO of Immunicon, an oncology diagnostics company, where he had previously held the position of Chief Operating Officer and General Manager, cancer products. He has also served as SVP of Sales and Marketing and General Manager, North America for Qiagen, Inc., and held leadership positions at Abbott Diagnostics, Chiron/Bayer, and BioCircuits. Mr. Hewett holds a B.S. from the McIntire School of Commerce at University of Virginia and a Masters in Management from the J.L. Kellogg Graduate School of Management at Northwestern University.
Robin Toft, President and CEO of Sanford Rose Associates® – Toft Group said: “We are extremely honored to have placed Mr. Hewett into his extraordinary role as CEO of SomaLogic, Inc. Mr. Hewett will transition into the CEO role previously held by CEO and Founder of SomaLogic, Dr. Larry Gold. Dr. Gold, who initiated the search for a new CEO, will remain Chairman of the Board and active advisor to Mr. Hewett and other senior managers at SomaLogic. We believe Mr. Hewett will make an outstanding contribution to the continued growth and development of SomaLogic, and congratulate him on his CEO appointment.We look forward to the continued success of both Mr. Hewett and our client, SomaLogic, Inc.”
“Dr. Gold and I are committed to working together to provide a seamless transition into our new roles as the company continues along its growth trajectory. Blending our experiences and decades of industry experience will allow us to best deliver upon SomaLogic’s mission to develop and commercialize breakthrough clinical diagnostic products that will transform healthcare. The talented team that Dr. Gold has built at SomaLogic is dedicated to improving the quality of life for people everywhere through continued discovery, development, and successful commercialization of proteomic technology today, and I am very excited to lead the company as Chief Executive Officer” said Mr. Hewett. “SomaLogic’
SomaLogic, Inc., (www.somalogic.com) is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colorado. The company's mission is to use its proprietary modified aptamer-based proteomic technologies to develop a wide range of enhanced protein-analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of health care by offering timely and accurate diagnostic information to physicians and their patients.
Sanford Rose Associates® - Toft Group (www.sanfordrose.net/
Robin Toft, President and CEO, at (858) 546-4801